Table 1B.
Patient characteristics and type of VTE prophylaxis in patients receiving LMWH or fondaparinux prophylaxis between January 2005 and December 2009. anova group comparisons using covariate analysis for type of thromboprophylaxis, gender and demographic parameters as variables
| LMWH n= 1495 | Fondaparinux n= 1994 | |||||
|---|---|---|---|---|---|---|
| Parameter | Gender | Mean | 95% CI | Mean | 95% CI | P value |
| History of VTE [%] | Male | 0.31 | 0.05, 1.06 | 0.56 | 0.19, 1.39 | 0.751 |
| Female | 1.46 | 0.82, 2.48 | 1.11 | 0.65, 1.81 | ||
| BMI [kg m−2] | Male | 28.0 | 27.6, 28.3 | 29.1 | 28.7, 29.4 | <0.001 |
| Female | 27.8 | 27.5, 28.2 | 28.9 | 28.6, 29.2 | ||
| Platelet count (Gpt l−1) | Male | 220.1 | 215.3, 224.8 | 195.6 | 191.0, 200.1 | <0.001 |
| Female | 239.7 | 235.4, 244.1 | 215.2 | 211.4, 219.0 | ||
| INR | Male | 1.074 | 1.07, 1.08 | 1.117 | 1.11, 1.12 | <0.001 |
| Female | 1.068 | 1.06, 1.08 | 1.11 | 1.105, 1.12 | ||
| aPTT (s) | Male | 29.0 | 28.6, 29.4 | 28.6 | 28.2, 29.0 | 0.044 |
| Female | 28.9 | 28.6, 29.3 | 28.5 | 28.2, 28.8 | ||
| Creatinine (µmol l−1) | Male | 73.22 | 71.94, 74.51 | 72.36 | 71.13, 73.59 | 0.211 |
| Female | 57.99 | 56.81, 59.17 | 57.12 | 56.10, 58.14 | ||
LMWH = low molecular weight heparin; aXa = anti-Factor Xa units.